Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial

Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial

Abstract Background Type 2 diabetes (T2D) is associated with renal impairment and vascular endothelial dysfunction. Therefore, this pathological connection is an important therapeutic target. Recent cardiovascular and renal outcome trials demonstrated that sodium glucose cotransporter 2 inhibitors (...

Full description

Bibliographic Details
Main Authors: Atsushi Tanaka, Michio Shimabukuro, Yosuke Okada, Kazuhiro Sugimoto, Akira Kurozumi, Keiichi Torimoto, Hiroyuki Hirai, Koichi Node, the PROCEED trial investigators
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Cardiovascular Diabetology
Subjects:
Chronic kidney disease (CKD)
Endothelial dysfunction
Ipragliflozin
Reactive hyperemia peripheral arterial tonometry (RH-PAT)
Sodium glucose cotransporter 2 inhibitor (SGLT2i)
Type 2 diabetes (T2D)
Online Access:http://link.springer.com/article/10.1186/s12933-020-01065-w

Internet

http://link.springer.com/article/10.1186/s12933-020-01065-w

Similar Items